252 related articles for article (PubMed ID: 31755366)
1. Targeting DNA methylation for treating triple-negative breast cancer.
Yu J; Zayas J; Qin B; Wang L
Pharmacogenomics; 2019 Nov; 20(16):1151-1157. PubMed ID: 31755366
[TBL] [Abstract][Full Text] [Related]
2. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine.
Yu J; Qin B; Moyer AM; Nowsheen S; Liu T; Qin S; Zhuang Y; Liu D; Lu SW; Kalari KR; Visscher DW; Copland JA; McLaughlin SA; Moreno-Aspitia A; Northfelt DW; Gray RJ; Lou Z; Suman VJ; Weinshilboum R; Boughey JC; Goetz MP; Wang L
J Clin Invest; 2018 Jun; 128(6):2376-2388. PubMed ID: 29708513
[TBL] [Abstract][Full Text] [Related]
3. The frequency of CpG and non-CpG methylation of Notch3 gene promoter determines its expression levels in breast cancer cells.
Xiao W; Liu X; Niu X; Li C; Guo Y; Tan J; Xiong W; Fan L; Li Y
Exp Cell Res; 2020 Jan; 386(2):111743. PubMed ID: 31770532
[TBL] [Abstract][Full Text] [Related]
4. Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines.
Al-Yousef N; Shinwari Z; Al-Shahrani B; Al-Showimi M; Al-Moghrabi N
Oncol Rep; 2020 Mar; 43(3):827-838. PubMed ID: 32020216
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.
Borges S; Döppler H; Perez EA; Andorfer CA; Sun Z; Anastasiadis PZ; Thompson E; Geiger XJ; Storz P
Breast Cancer Res; 2013 Aug; 15(2):R66. PubMed ID: 23971832
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of DNMT1 and ERRα crosstalk suppresses breast cancer via derepression of IRF4.
Vernier M; McGuirk S; Dufour CR; Wan L; Audet-Walsh E; St-Pierre J; Giguère V
Oncogene; 2020 Oct; 39(41):6406-6420. PubMed ID: 32855526
[TBL] [Abstract][Full Text] [Related]
7. DNMT1: A key drug target in triple-negative breast cancer.
Wong KK
Semin Cancer Biol; 2021 Jul; 72():198-213. PubMed ID: 32461152
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Regulation of CDH1 Is Altered after HOXB7-Silencing in MDA-MB-468 Triple-Negative Breast Cancer Cells.
Paço A; Leitão-Castro J; Freitas R
Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34680970
[TBL] [Abstract][Full Text] [Related]
9. Activation of silenced tumor suppressor genes in prostate cancer cells by a novel energy restriction-mimetic agent.
Lin HY; Kuo YC; Weng YI; Lai IL; Huang TH; Lin SP; Niu DM; Chen CS
Prostate; 2012 Dec; 72(16):1767-78. PubMed ID: 22539223
[TBL] [Abstract][Full Text] [Related]
10. Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine in anaplastic large cell lymphoma.
Hassler MR; Klisaroska A; Kollmann K; Steiner I; Bilban M; Schiefer AI; Sexl V; Egger G
Biochimie; 2012 Nov; 94(11):2297-307. PubMed ID: 22687603
[TBL] [Abstract][Full Text] [Related]
11. Promoter methylation status of tumor suppressor genes and inhibition of expression of DNA methyltransferase 1 in non-small cell lung cancer.
Liu B; Song J; Luan J; Sun X; Bai J; Wang H; Li A; Zhang L; Feng X; Du Z
Exp Biol Med (Maywood); 2016 Aug; 241(14):1531-9. PubMed ID: 27190263
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
Su Y; Hopfinger NR; Nguyen TD; Pogash TJ; Santucci-Pereira J; Russo J
J Exp Clin Cancer Res; 2018 Dec; 37(1):314. PubMed ID: 30547810
[TBL] [Abstract][Full Text] [Related]
13. Induction of the estrogen receptor by ablation of DNMT1 in ER-negative breast cancer cells.
Adams PD; Cairns P
Cancer Biol Ther; 2003; 2(5):557-8. PubMed ID: 14614326
[No Abstract] [Full Text] [Related]
14. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
15. Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.
Cooper SJ; von Roemeling CA; Kang KH; Marlow LA; Grebe SK; Menefee ME; Tun HW; Colon-Otero G; Perez EA; Copland JA
Mol Cancer Ther; 2012 Oct; 11(10):2105-15. PubMed ID: 22826467
[TBL] [Abstract][Full Text] [Related]
16. Oxidative stress-induced epigenetic changes associated with malignant transformation of human kidney epithelial cells.
Mahalingaiah PK; Ponnusamy L; Singh KP
Oncotarget; 2017 Feb; 8(7):11127-11143. PubMed ID: 27655674
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor.
Gray SG; Baird AM; O'Kelly F; Nikolaidis G; Almgren M; Meunier A; Dockry E; Hollywood D; Ekström TJ; Perry AS; O'Byrne KJ
Int J Mol Med; 2012 Dec; 30(6):1505-11. PubMed ID: 23007409
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A.
Szarc Vel Szic K; Declerck K; Crans RAJ; Diddens J; Scherf DB; Gerhäuser C; Vanden Berghe W
Oncotarget; 2017 Jun; 8(25):40434-40453. PubMed ID: 28467815
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma.
Chaisaingmongkol J; Popanda O; Warta R; Dyckhoff G; Herpel E; Geiselhart L; Claus R; Lasitschka F; Campos B; Oakes CC; Bermejo JL; Herold-Mende C; Plass C; Schmezer P
Oncogene; 2012 Dec; 31(49):5108-16. PubMed ID: 22286769
[TBL] [Abstract][Full Text] [Related]
20. Modulation of DNA methylation by a sesquiterpene lactone parthenolide.
Liu Z; Liu S; Xie Z; Pavlovicz RE; Wu J; Chen P; Aimiuwu J; Pang J; Bhasin D; Neviani P; Fuchs JR; Plass C; Li PK; Li C; Huang TH; Wu LC; Rush L; Wang H; Perrotti D; Marcucci G; Chan KK
J Pharmacol Exp Ther; 2009 May; 329(2):505-14. PubMed ID: 19201992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
